Core Insights - The OVATION 2 Study results reinforce the efficacy of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer, demonstrating significant anti-cancer immune cytokine production post-treatment [1][3] - The ongoing Phase 3 trial, OVATION 3, aims to expand patient recruitment with four sites activated and plans for further site expansion [1][4] Study Details - The Phase 2 OVATION 2 Study involved 112 participants receiving IMNN-001 (100 mg/m administered intraperitoneally weekly) alongside standard neoadjuvant and adjuvant chemotherapy [2][8] - Translational data showed a positive shift in the tumor microenvironment (TME), with increased immune stimulatory T cell ratios and decreased immunosuppressive cells in the majority of participants post-treatment [6][8] Efficacy and Safety - IMNN-001 treatment resulted in a median overall survival (OS) increase of 13 months (HR 0.70) and a median progression-free survival (PFS) increase of 3 months (HR 0.79) compared to standard care [5][11] - The treatment demonstrated a favorable safety profile, with limited to no systemic toxicities reported [3][6] Future Directions - The OVATION 3 Study is currently enrolling patients at four sites, with up to 46 additional sites being considered for activation to accelerate enrollment [7][4] - The positive results from the OVATION 2 Study have led to invitations for presentations at major oncology conferences and publications in peer-reviewed journals [7]